Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb

Journal of Gene Medicine

Volumn 13, Issue 9, 2011, Pages 470-477

  Liang, Yaming ^a   Qiu, Hongmin ^a   Glinka, Yelena ^b   Lazarus, Alan H ^b   Ni, Heyu ^b   Prud'homme, Gerald J ^b   Wang, Qinghua ^a,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

B cell; Exendin 4; Fc RIIb; GLP 1; IgG Fc; Immunogenicity

Indexed keywords

EXENDIN 4; FC RECEPTOR IIB; IMMUNOGLOBULIN G1; PLASMID VECTOR; PROTEIN; RECOMBINANT EXENDIN 4 FC RECEPTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; XENOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SYNTHESIS; ELECTROPORATION; GENE TRANSFER; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; PLASMIDS; PROTEIN BINDING; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; VENOMS;

MUS;

EID: 80053423626     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1598     Document Type: Article

References (37)

1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
2. Leavy O. Therapeutic antibodies: past, present and future. Nat Rev Immunol 2010; 10: 297.
3. Lee AY, Chey WY, Choi J, Jeon JS. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82: 114-117.
4. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006; 6: 243-273.
5. Drew DR, Lightowlers M, Strugnell RA. Vaccination with plasmid DNA expressing antigen from genomic or cDNA gene forms induces equivalent humoral immune responses. Vaccine. 1999 18: 692-702.
6. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
7. Brubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 2010; 151: 1984-1989.
8. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
9. Kumar M, Hunag Y, Glinka Y, Prud'homme GJ, Wang Q. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther 2007; 14: 162-172.
10. Soltani N, Kumar M, Glinka Y, Prud'homme GJ, Wang Q. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 2007; 14: 981-988.
11. Wang Q, Chen K, Liu R, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One 2010; 5: e12734.
12. Ravetch JV, Lanier LL. 1Immune inhibitory receptors. Science 2000; 290: 84-89.
13. Tarasenko T, Dean JA, Bolland S. FcgammaRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity 2007; 40: 409-417.
14. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc (gamma)RIIB. Nature 1996; 383: 263-266.
15. Nadler MJ, Chen B, Anderson JS, Wortis HH, Neel BG. Protein-tyrosine phosphatase SHP-1 is dispensable for FcgammaRIIB-mediated inhibition of B cell antigen receptor activation. J Biol Chem 1997; 272: 20038-20043.
16. Horton HM, Chu SY, Ortiz EC, et al. Antibody-mediated coengagement of Fc{gamma}RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol 2011; 186: 4223-4233.
17. Uray K, Medgyesi D, Hilbert A, Sarmay G, Gergely J, Hudecz F. Synthesis and receptor binding of IgG1 peptides derived from the IgG Fc region. J Mol Recognit 2004; 17: 95-105.
18. Zakut R, Cohen J, Givol D. Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11. Nucleic Acids Res 1980; 8: 3591-3601.
19. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8week-old db/db mice. Diabetologia 2002; 45: 1263-1273.
20. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
21. Pohl M, Wank SA. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem 1998; 273: 9778-9784.
22. Ahangari G, Ostadali MR, Rabani A, Rashidian J, Sanati MH, Zarindast MR. Growth hormone antibodies formation in patients treated with recombinant human growth hormone. Int J Immunopathol Pharmacol 2004; 17: 33-38.
23. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005; 25: 1-18.
24. Larrick JW, Fry KE. Recombinant antibodies. Hum Antibodies Hybridomas 1991; 2: 172-189.
25. Weir AN, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson AD. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 2002; 30: 512-516.
26. Jiang XR, Song A, Bergelson S, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10: 101-111.
27. 2+ mobilization in Fc gammaR-transfected human B cells. Int Immunol 1998; 10: 141-146.
28. D'Ambrosio D, Fong DC, Cambier JC. The SHIP phosphatase becomes associated with Fc gammaRIIB1 and is tyrosine phosphorylated during 'negative' signaling. Immunol Lett 1996; 54: 77-82.
29. Aman MJ, Lamkin TD, Okada H, Kurosaki T, Ravichandran KS. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J Biol Chem 1998; 273: 33922-33928.
30. Sarmay G, Koncz G, Gergely J. Human type II Fcgamma receptors inhibit B cell activation by interacting with the p21 (ras)-dependent pathway. J Biol Chem 1996; 271: 30499-30504.
31. Harnett MM, Katz E, Ford CA. Differential signalling during B-cell maturation. Immunol Lett 2005; 98: 33-44.
32. Prud'homme GJ, Draghia-Akli R, Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther 2007; 14: 553-564.
33. Baggio LL, Holland D, Wither J, Drucker DJ. Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice. Diabetes 2006; 55: 1562-1570.
34. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10: 328-343.
35. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-1512.
36. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-3725.
37. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 2003; 40: 585-593.